Stilgenbauer, S., Ilhan, O., Kisro, J., Mahé, B., Mikuskova, E., & Bosch, F. (2021). Safety and efficacy of obinutuzumab alone or with chemotherapy in previously untreated or relapsed/refractory chronic lymphocytic leukaemia patients: Final analysis of the Phase IIIb GREEN study.
Citación estilo ChicagoStilgenbauer, Stephan, Osman Ilhan, Jens Kisro, Béatrice Mahé, Eva Mikuskova, y Francesc Bosch. Safety and Efficacy of Obinutuzumab Alone or With Chemotherapy in Previously Untreated or Relapsed/refractory Chronic Lymphocytic Leukaemia Patients: Final Analysis of the Phase IIIb GREEN Study. 2021.
Cita MLAStilgenbauer, Stephan, et al. Safety and Efficacy of Obinutuzumab Alone or With Chemotherapy in Previously Untreated or Relapsed/refractory Chronic Lymphocytic Leukaemia Patients: Final Analysis of the Phase IIIb GREEN Study. 2021.